Patents by Inventor Rajesh Khanna

Rajesh Khanna has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250017940
    Abstract: The present invention relates to compounds of Formula (I): where R1, R2, X, s, and p are as defined herein. The present invention also relates to compounds of Formula (II), Formula (III), and: where R1a, R1b, R1d, R2a, R2b, R3b, X, Z, Z1, Z2, s, and p are as defined herein. Methods of using these compounds to regulate Cav2.2.target double-stranded RNA and to treat diseases and disorders, e.g., chronic pain, are also disclosed.
    Type: Application
    Filed: June 28, 2024
    Publication date: January 16, 2025
    Applicants: New York University, University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Rajesh KHANNA, Carlos J. CAMACHO
  • Publication number: 20240397132
    Abstract: Systems and methods are provided for determining whether to extend a recording of a media asset based on analyzing user data. A media guidance application may determine that a media asset is recording during a scheduled time slot that has a start time and an end time. The media guidance application may determine that the media asset will be transmitted outside of the scheduled time slot based on inputs from a plurality of users. In response to determining that the media asset will be transmitted outside of the scheduled time, the media guidance application may extend the recording of the media asset beyond the scheduled time slot by a predetermined amount of time.
    Type: Application
    Filed: May 28, 2024
    Publication date: November 28, 2024
    Inventor: Rajesh Khanna
  • Patent number: 12034990
    Abstract: Systems and methods are provided for determining whether to extend a recording of a media asset based on analyzing user data. A media guidance application may determine that a media asset is recording during a scheduled time slot that has a start time and an end time. The media guidance application may determine that the media asset will be transmitted outside of the scheduled time slot based on inputs from a plurality of users. In response to determining that the media asset will be transmitted outside of the scheduled time, the media guidance application may extend the recording of the media asset beyond the scheduled time slot by a predetermined amount of time.
    Type: Grant
    Filed: January 25, 2022
    Date of Patent: July 9, 2024
    Assignee: Rovi Guides, Inc.
    Inventor: Rajesh Khanna
  • Patent number: 11883403
    Abstract: The present invention relates to a tablet comprising Afatinib or a pharmaceutically acceptable salt thereof, wherein the tablet is obtained by direct compression. The present invention further relates to a process for manufacturing a tablet of the invention as well as the use of the tablet of the invention.
    Type: Grant
    Filed: March 22, 2022
    Date of Patent: January 30, 2024
    Assignee: Fresenius Kabi Oncology Ltd.
    Inventors: Rajesh Khanna, Neeraj Kumar, Vijay Kumar Sharma, Ankit Gaur, Dhiraj Khattar
  • Patent number: 11877356
    Abstract: Systems, methods and computer software are disclosed for providing a bubble network are described. In one embodiment, a method is disclosed including providing an isolated base station having a coverage area, providing a local HetNet Gateway (HNG) disposed within the coverage area and in communication with the isolated base station, providing a local Evolved Packet Core (EPC) in communication with the local HNG and disposed within the coverage area, and wherein the bubble network is disconnected from a mobile operator core network.
    Type: Grant
    Filed: July 26, 2022
    Date of Patent: January 16, 2024
    Assignee: Parallel Wireless, Inc.
    Inventors: Rajesh Khanna, Patrick McPhee, Gaurav Kumar
  • Publication number: 20240002361
    Abstract: Disclosed are compositions and methods for treating, preventing, or reducing neuropathic pain or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in a patient. The compositions contain, or the methods involve, compounds that inhibit neuropilin receptor 1 signaling. The compounds are present in amounts effective to treat, prevent, or reduce one or more symptoms associated with neuropathic pain or SARS-CoV-2 in a patient.
    Type: Application
    Filed: November 17, 2021
    Publication date: January 4, 2024
    Inventors: Rajesh Khanna, Aubin Moutal, Samantha Perez-Miller
  • Publication number: 20230365544
    Abstract: This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a piperazine or piperidine structure which function as either inhibitors of pan-T-type calcium channel activity (e.g., CaV3.1 voltage gated calcium channel activity) (e.g., CaV3.2 voltage gated calcium channel activity) (e.g., CaV3.3 voltage gated calcium channel activity) (e.g., depolarization-induced calcium influx) or specific inhibitors of CaV3.2 voltage gated calcium channel activity, and their use as therapeutics for the treatment and/or prevention of pan-T-type calcium channel related pain (e.g., CaV3.1 related pain) (e.g., CaV3.2 related pain) (e.g., CaV3.3 related pain) (e.g., HIV-associated peripheral sensory neuropathy, chemotherapy-induced peripheral neuropathy (CIPN), spinal nerve ligation (SNL) induced neuropathy) (e.g., tonic, neuropathic, and/or inflammatory pain) and related conditions.
    Type: Application
    Filed: December 20, 2022
    Publication date: November 16, 2023
    Inventors: Jun Wang, Rajesh Khanna
  • Publication number: 20230233544
    Abstract: Dysregulation of TAF1 function by various mechanisms can lead to disease in the central nervous system, such as the TAF1 Intellectual Disability (ID) Syndrome which currently has no therapeutic treatments. The present invention indicates that a novel T-type calcium channel enhancer, such as SAK3, has disease-modifying effects in animal models of TAF1 editing. In addition, the present invention provides insights into the molecular mechanism by which SAK3 exerts in pharmacologic effects. Moreover, the present findings imply that the T-Type voltage-gated calcium channels are novel molecular targets to develop therapeutics to treat TAF1 ID syndrome and that SAK3 is an attractive drug candidate to treat TAF1 associated neurologic disorders.
    Type: Application
    Filed: June 11, 2021
    Publication date: July 27, 2023
    Inventors: Mark A. Nelson, Rajesh Khanna, Janakiraman Udaiyappan, Dhanalakshmi Shankara Raman
  • Publication number: 20230192674
    Abstract: This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a piperazine or piperidine structure which function as inhibitors of the CaV3.2 voltage gated calcium channel activity (e.g., depolarization-induced calcium influx), and their use as therapeutics for the treatment and/or prevention of CaV3.2 related pain e g., HIV-associated peripheral sensory neuropathy, chemotherapy-induced peripheral neuropathy (CIPN), spinal nerve ligation (SNL) induced neuropathy) and related conditions.
    Type: Application
    Filed: May 12, 2021
    Publication date: June 22, 2023
    Inventors: Jun Wang, Rajesh Khanna
  • Patent number: 11607557
    Abstract: Devices and systems for treating based on light therapy are disclosed. One example device includes an eyewear configured for placement in front of an eye to allow light to reach the eye, and one or more filters having transmission spectra within a range that approximately spans 450 to 570 nm associated with blue or green light. The one or more filters is configured to block light spectra outside of said range and to allow the blue or green light to reach the eye for administering light therapy to a subject exhibiting pain.
    Type: Grant
    Filed: October 30, 2020
    Date of Patent: March 21, 2023
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
    Inventors: Mohab M. Ibrahim, Rajesh Khanna
  • Patent number: 11502394
    Abstract: A communications backpack is disclosed. In one embodiment, the communications backpack includes a backpack; a Radio Area Network (RAN) device in mechanical communication with the backpack; a mini-server in mechanical communication with the backpack and in electrical communication with the RAN device; at least one hot swappable battery in mechanical communication with the backpack and in electrical communication with the RAN device and the mini-server; at least two antennas, wherein the two antennas are stored in a first position alongside the backpack and are movable to a second position where the two antennas are coupled to the backpack and in electrical communication with the RAN device; and wherein the communications backpack provides a coverage area of up to 3 kilometers (km).
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: November 15, 2022
    Assignee: Parallel Wireless, Inc.
    Inventors: Jason Tiner, Rajesh Khanna, Patrick McPhee
  • Publication number: 20220361290
    Abstract: Systems, methods and computer software are disclosed for providing a bubble network are described. In one embodiment, a method is disclosed including providing an isolated base station having a coverage area, providing a local HetNet Gateway (HNG) disposed within the coverage area and in communication with the isolated base station, providing a local Evolved Packet Core (EPC) in communication with the local HNG and disposed within the coverage area, and wherein the bubble network is disconnected from a mobile operator core network.
    Type: Application
    Filed: July 26, 2022
    Publication date: November 10, 2022
    Inventors: Rajesh Khanna, Patrick McPhee, Gaurav Kumar
  • Patent number: 11399414
    Abstract: Systems, methods and computer software are disclosed for providing a bubble network are described. In one embodiment, a method is disclosed including providing an isolated base station having a coverage area, providing a local HetNet Gateway (HNG) disposed within the coverage area and in communication with the isolated base station, providing a local Evolved Packet Core (EPC) in communication with the local HNG and disposed within the coverage area, and wherein the bubble network is disconnected from a mobile operator core network.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: July 26, 2022
    Assignee: Parallel Wireless, Inc.
    Inventors: Rajesh Khanna, Patrick McPhee, Gaurav Kumar
  • Publication number: 20220211705
    Abstract: The present invention relates to a tablet comprising Afatinib or a pharmaceutically acceptable salt thereof, wherein the tablet is obtained by direct compression. The present invention further relates to a process for manufacturing a tablet of the invention as well as the use of the tablet of the invention.
    Type: Application
    Filed: March 22, 2022
    Publication date: July 7, 2022
    Applicant: FRESENIUS KABI ONCOLOGY LIMITED
    Inventors: Rajesh KHANNA, Neeraj KUMAR, Vijay Kumar SHARMA, Ankit GAUR, Dhiraj KHATTAR
  • Publication number: 20220151923
    Abstract: The present invention relates to a stable liquid pharmaceutical composition of pemetrexed for parenteral administration. The invention provides composition comprising pemetrexed diacid, an organic amine and cyclodextrin. The composition may further comprise an inert gas. The composition can be ready to use infusion solution of pemetrexed diacid or liquid concentrate formulation to be diluted before administration to the patient. The present invention further relates to a process for manufacturing the compositions as well as use of the compositions of the invention for the treatment of malignant pleural mesothelioma and non-small cell lung cancer.
    Type: Application
    Filed: September 27, 2021
    Publication date: May 19, 2022
    Applicant: FRESENIUS KABI ONCOLOGY LIMITED
    Inventors: Dhiraj KHATTAR, Rajesh KHANNA, Abhilasha YADAV, Vikas BHANDARI, Sameer Ramanlal MODI, . HEMLATA
  • Publication number: 20220150563
    Abstract: Systems and methods are provided for determining whether to extend a recording of a media asset based on analyzing user data. A media guidance application may determine that a media asset is recording during a scheduled time slot that has a start time and an end time. The media guidance application may determine that the media asset will be transmitted outside of the scheduled time slot based on inputs from a plurality of users. In response to determining that the media asset will be transmitted outside of the scheduled time, the media guidance application may extend the recording of the media asset beyond the scheduled time slot by a predetermined amount of time.
    Type: Application
    Filed: January 25, 2022
    Publication date: May 12, 2022
    Inventor: Rajesh Khanna
  • Patent number: 11265590
    Abstract: Systems and methods are provided for determining whether to extend a recording of a media asset based on analyzing user data. A media guidance application may determine that a media asset is recording during a scheduled time slot that has a start time and an end time. The media guidance application may determine that the media asset will be transmitted outside of the scheduled time slot based on inputs from a plurality of users. In response to determining that the media asset will be transmitted outside of the scheduled time, the media guidance application may extend the recording of the media asset beyond the scheduled time slot by a predetermined amount of time.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: March 1, 2022
    Assignee: Rovi Guides, Inc.
    Inventor: Rajesh Khanna
  • Patent number: 11208397
    Abstract: This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a piperidinyl-benzoimidazole structure which function as antagonists of small ubiquitin like modifier (SUMO) related modification (SUMOylation) of collapsin response mediator protein 2 (CRMP2), and their use as therapeutics for the treatment of voltage gated sodium channel 1.7 (Nav1.7) related itch, anosmia, migraine event, and/or pain (e.g., neuropathic pain).
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: December 28, 2021
    Assignee: Arizona Board of Regents on Behalf of the University of Arizona
    Inventors: May Khanna, Rajesh Khanna, Vijay Gokhale, Reena Chawla
  • Patent number: 11020391
    Abstract: The present invention provides compounds that can modulate the amount of Nav1.7 protein, a key protein in pain signaling, that is present in the cellular surface and methods for using such compounds. In particular, compounds of the invention modulate the amount of Nav1.7 protein on the cellular surface by modulating SUMOylation of CRMP2. Thus, compounds of the invention can be used to treat various clinical conditions associated with the presence and/or activation of Nav1.7 protein on the cellular surface and/or SUMOylation of CRMP2.
    Type: Grant
    Filed: October 8, 2019
    Date of Patent: June 1, 2021
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
    Inventors: May Khanna, Rajesh Khanna, Vijay Gokhale, Reena Chawla
  • Publication number: 20210060355
    Abstract: Devices and systems for treating based on light therapy are disclosed. One example device includes an eyewear configured for placement in front of an eye to allow light to reach the eye, and one or more filters having transmission spectra within a range that approximately spans 450 to 570 nm associated with blue or green light. The one or more filters is configured to block light spectra outside of said range and to allow the blue or green light to reach the eye for administering light therapy to a subject exhibiting pain.
    Type: Application
    Filed: October 30, 2020
    Publication date: March 4, 2021
    Inventors: Mohab M. Ibrahim, Rajesh Khanna